The E3 ubiquitin ligase, RNF219, suppresses CNOT6L expression to exhibit antiproliferative activity

Area of Science:

• Molecular Biology
• Gene Regulation
• Cancer Biology

Background:

• The CCR4-NOT complex is crucial for posttranscriptional gene regulation, but its mechanisms remain unclear.
• Identifying novel interacting partners can elucidate the CCR4-NOT complex's function.

Purpose of the Study:

• To identify novel interacting partners of the CCR4-NOT complex.
• To investigate the functional role of RNF219 in gene regulation and cell proliferation.
• To explore the potential link between RNF219 and triple-negative breast cancer prognosis.

Main Methods:

• Mass spectrometry was used to identify CCR4-NOT interacting proteins.
• Pull-down assays and in vitro ubiquitination assays were performed to characterize RNF219-CNOT1 interaction and RNF219's enzymatic activity.
• RNF219 knockdown experiments in HEK293T cells were conducted to assess its effect on CNOT6L expression and cell proliferation.

Main Results:

• RNF219 was identified as a novel CCR4-NOT interacting partner, binding to the CNOT1 DUF3819 domain.
• RNF219 exhibits ubiquitin ligase activity and directly ubiquinates CNOT6L.
• RNF219 knockdown led to increased CNOT6L expression and enhanced cell proliferation, suggesting RNF219 has antiproliferative activity.
• RNF219 suppresses CNOT6L expression through proteasome-mediated protein degradation.

Conclusions:

• RNF219 negatively regulates CNOT6L expression, likely through proteasomal degradation, thereby influencing cell proliferation.
• Low RNF219 expression is associated with poor prognosis in triple-negative breast cancer patients.
• Further research is needed to confirm if RNF219's role in cancer progression is mediated by the CCR4-NOT complex.